{"organizations": [], "uuid": "e0cadb03d875799441b5781b744d8de1f33181ba", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/idUSL8N1QD0UB", "country": "US", "domain_rank": 408, "title": "BRIEF-Galapagos FY Net Result Swings To Loss Of 115.7 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T09:15:00.000+02:00", "replies_count": 0, "uuid": "e0cadb03d875799441b5781b744d8de1f33181ba"}, "author": "", "url": "https://www.reuters.com/article/idUSL8N1QD0UB", "ord_in_thread": 0, "title": "BRIEF-Galapagos FY Net Result Swings To Loss Of 115.7 Million Euros", "locations": [], "entities": {"persons": [{"name": "galapagos", "sentiment": "none"}, {"name": "finch", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "finch", "sentiment": "none"}, {"name": "gilead", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 23, 2018 / 7:19 AM / Updated 2 hours ago BRIEF-Galapagos FY Net Result Swings To Loss Of 115.7 Million Euros Reuters Staff 2 Min Read Feb 23 (Reuters) - GALAPAGOS: * REPORTED ON THURSDAY FY NET LOSS OF €115.7 MILLION, COMPARED TO NET PROFIT OF €54.0 MILLION IN 2016 * FY GROUP REVENUES INCREASED BY €4.3 MILLION TO €155.9 MILLION * FY OPERATING LOSS INCREASED BY €78.3 MILLION TO €89.8 MILLION * FY OPERATIONAL CASH BURN OF €154.1 MILLION * CASH BALANCE INCREASED BY €171.5 MILLION TO €1,152.4 MILLION AT YEAR-END * IN 2018 AIMS TO REPORT TOPLINE RESULTS WITH THE FINCH 2 (RHEUMATOID ARTHRITIS), EQUATOR (PSORIATIC ARTHRITIS), TORTUGA (ANKYLOSING SPONDILITIS) FILGOTINIB TRIALS AS WELL AS A DECISION TO CONTINUE TO PHASE 3 IN SELECTION (ULCERATIVE COLITIS) * IN 2018 COLLABORATION PARTNER GILEAD EXPECTS TO COMPLETE RECRUITMENT OF FINCH 1 AND FINCH 3, THE REMAINING RA PHASE 3 TRIALS WITH FILGOTINIB * IN 2018 IN CYSTIC FIBROSIS WE ANTICIPATE THE READOUT OF THE PELICAN PATIENT TRIAL AND AN INTERIM READOUT IN FALCON * IN 2018 AIMS TO INITIATE PIVOTAL TRIALS WITH GLPG1690 (IPF) AND PHASE 2 TRIALS WITH GLPG1205 (IPF), AN ADDITIONAL CF TRIPLE COMBINATION, GLPG1972 (OSTEOARTHRITIS), AND MOR106 (ATOPIC DERMATITIS) * EXPECTS AN OPERATIONAL CASH BURN BETWEEN €220 AND €240 MILLION IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)", "external_links": [], "published": "2018-02-23T09:15:00.000+02:00", "crawled": "2018-02-23T09:34:51.024+02:00", "highlightTitle": ""}